Cancer Biomarkers: Minimal and Noninvasive Early Diagnosis and Prognosis 1e uitgave

Brief Description: "Preface According to the American Cancer Society report, "by 2030, the global cancer burden is expected to nearly double, growing to 21.4 million cases and 13.2 million deaths." Early diagnosis improves treatment efficacy and quality of life as well as reduces the cost for disease management. However, the development of molecular markers for early cancer diagnosis is always a challenge. Some fundamental principles in medical practice are (a) primum non nocere, a Latin phrase that means "first, do no harm," and (b) even when a patient's prognosis is poor, the physician must do his or her best for improving quality of the patient's life. Therefore, noninvasive or minimally invasive cancer diagnostic methods are of choice that can avoid complications of biopsy and other unfavorable impacts on patient's health. In this context, patients' easily collectable biospecimens such as blood, serum, plasma, urine, stool, sputum, saliva, etc. -based molecular markers having high specificity and sensitivity in early diagnosis are emerging rapidly and in many instances such markers are also emerging as next-generation prognostic indicators and personalized therapeutics and precision medicine. Several patents have been filed and/or granted on such markers, and a number of health-care companies and authorities currently use or focus on the development of such markers. The significance of clinical validation approaches of several markers has been discussed in different chapters. This book, Cancer Biomarkers: Noninvasive Early Diagnosis and Prognosis, reflects the rapid expansion of important scientific, technological, clinical, and translational aspects of noninvasive or minimally invasive molecular cancer biomarkers and their applications along with other conventional markers"--Provided by publisher. Biographical Note: Debmalya Barh (MSc, MTech, MPhil, PhD, PGDM) is the founder and president of the Institute of Integrative Omics and Applied Biotechnology (IIOAB), India. He is a consultant biotechnologist and an active researcher in integrative omics based biomarkers, targeted drug discovery, and personalized medicine in cancer, neurodisorders, and cardiovascular, infectious, and metabolic diseases. He works with nearly 400 esteemed researchers from 30 35 countries and he has more than 100 high-impact publications. He has edited ten books in the field of omics. He also serves as an editorial and review board member for several highly respected international journals. Dr. Angelo Carpi is a clinical professor of medicine at the Pisa University Medical School, Pisa, Italy. He received his MD and postgraduate diplomas in internal medicine and nuclear medicine from the University of Pisa and his diploma of qualification on peptide hormones from the Collegio Medico Giuridico-Scuola Normale Superiore and the Scuola Superiore Sant Anna, Pisa, Italy. His clinical practice and research included thyroid and breast tumors. He has authored about 300 publications included in PubMed. He is a member of the editorial boards of international journals such as "Biomedicine & Pharmacotherapy" and "Frontiers in Bioscience." Dr. Mukesh Verma is a program director and chief in the Methods and Technologies Branch (MTB), Epidemiology and Genomics Research Program (EGRP) of the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI), National Institutes of Health (NIH). Dr. Verma received his MSc from Pantnagar University and his PhD from Banaras Hindu University. He did postdoctoral research at George Washington University and was a faculty member at Georgetown University. He has published 128 research articles, book chapters, and reviews, and has edited three books in the field of cancer epigenetics and epidemiology. Mehmet Gunduz, MD, PhD, is a professor of otolaryngology and medical genetics, Faculty of Medicine, Turgut Ozal University, Turkey. He graduated from Medical School Hacettepe University in 1990, and completed his residency in otolaryngology at the same university. He received his PhD from Okayama University and Wakayama Medical University, Japan, and is medical board certified from both the Turkish and Japanese certification authorities. One of the pioneers in identifying ING family tumor suppressors, Dr. Gunduz has contributed to more than 150 international publications, 3,000 citations, several book chapters, and over 200 presentations in national and international conferences."Marc Notes: Includes bibliographical references and index.; Preface According to the American Cancer Society report, by 2030, the global cancer burden is expected to nearly double, growing to 21.4 million cases and 13.2 million deaths. Early diagnosis improves treatment efficacy and quality of life as well as reduces the cost for disease management. However, the development of molecular markers for early cancer diagnosis is always a challenge. Some fundamental principles in medical practice are (a) primum non nocere, a Latin phrase that means first, do no harm, and (b) even when a patient's prognosis is poor, the physician must do his or her best for improving quality of the patient's life. Therefore, noninvasive or minimally invasive cancer diagnostic methods are of choice that can avoid complications of biopsy and other unfavorable impacts on patient's health. In this context, patients' easily collectable biospecimens such as blood, serum, plasma, urine, stool, sputum, saliva, etc. -based molecular markers having high specificity and sensitivity in early diagnosis are emerging rapidly and in many instances such markers are also emerging as next-generation prognostic indicators and personalized therapeutics and precision medicine. Several patents have been filed and/or granted on such markers, and a number of health-care companies and authorities currently use or focus on the development of such markers. The significance of clinical validation approaches of several markers has been discussed in different chapters. This book, Cancer Biomarkers: Noninvasive Early Diagnosis and Prognosis, reflects the rapid expansion of important scientific, technological, clinical, and translational aspects of noninvasive or minimally invasive molecular cancer biomarkers and their applications along with other conventional markers--Provided by publisher. Table of Contents: Foreword -- Preface -- Editors -- Contributors -- Part I. General and Technical Aspects -- 1. Quality Control and Ethical Issues of Cancer Biomarker Discovery / Anjana Munshi, Vandana Sharma -- 2. Imaging Techniques in Cancer Diagnosis / Mohomed Abd El-Salam, Sonia Reda, Salwa Lotfi, Tamer Refaat, Eman El-Abd -- 3. Role of PET in Cancer Diagnosis / Silvia Taralli, Antonella Stefanelli, Giorgio Treglia -- 4. Innovative Tools for Early Detection of Cancer / Ali Tiss, Amal Hasan, Abdelkrim Khadir, Mohammed Dehbi, Said Dermime -- 5. Noninvasive Nanodiagnostics for Cancer / Sandhiya Selvarajan, Melvin George, Suresh Kumar -- 6. Mitochondrial DNA in Early Cancer Diagnosis and Screening / Mukesh Verma, Neelesh Agarwal, Mudit Verma -- 7. Circulating miRNA Biomarkers in Various Solid Cancers / Martina Redova, Hana Mlcochova, Ondrej Slaby -- 8. Stem Cell Biomarkers in Early Diagnosis, Prognosis, and Therapy of Cancer / Dipali Dhawan, Harish Padh -- 9. Salivary Biomarkers in Early Diagnosis and Monitoring of Cancer / Saroj K. Basak, Eri S. Srivatsan -- Part II. Brain and Head and Neck Cancers -- 10. Biomarkers for Brain Gliomas / Yusuf Izci -- 11. Noninvasive Biomarkers in Head and Neck Squamous Cell Carcinoma / Anand Kumar, Mumtaz Ahmad Ansari, Vivek Srivastava -- 12. Biological Markers in Oral Squamous Cell Carcinoma / Mario PErez-Sayans GarcIa, Danielle Resende Camisasca, Abel GarcIa GarcIa, Simone de Queiroz Chaves LourenCo, Anastasios Markopoulos -- Part III. Gastrointestinal Cancers -- 13. Biomarkers for Gastric Cancer and the Related Premalignant Conditions / Marcis Leja, Jan Bornschein, Juozas Kupcinskas, Peter Malfertheiner -- 14. Biomarkers in Esophageal Adenocarcinoma / Simon J. W. Monkhouse, J. Muhlschlegel, H. Barr -- 15. Biomarkers for Diagnosis and Metastasis of Hepatocellular Carcinoma / Dengfu Yao, Min Yao, Xiaodi Yan, Li Wang, Zhizhen Dong -- 16. Noninvasive Early Markers in Gallbladder Cancer / Mumtaz Ahmad Ansari, Ruhi Dixit, Vijay Kumar Shukla -- 17. Noninvasive Early Markers in Pancreatic Cancer / Aleksandra Nikolic -- Part IV. Lung Cancer and Mesothelioma -- 18. Noninvasive Early Markers in Lung Cancer / Mukesh Verma, Debmalya Barh, Neha Jain -- 19. Exhaled Volatile Organic Compounds as Noninvasive Early Molecular Markers in Lung Cancer: Bridging the Gap from Bench to Bedside / Meggie Hakim, Ulrike Tisch, Michael Unger, Hossam Haick -- Part V. Urological Cancers -- 20. Noninvasive Early Molecular Biomarkers in Kidney Cancer / Brian W. Cross, Jonathan Huang, Viraj A. Master -- 21. Novel Oncomarkers Used for Earlier Detection of Bladder Carcinoma / Miroslava BilecovA-RabajdovA, Peter Urban, MAria MarekovA, Vincent Nagy -- 22. Screening for Prostate Cancer: New Markers and Future Aspects / Nigel P. Murray -- Part VI. Gynecological and Endocrine Cancers -- 23. Early Biomarkers in Breast Cancer / Ruchika Kaul-Ghanekar, Snehal Suryavanshi, Prema Raina -- 24. Noninvasive Biomarkers in Ovarian Cancer / Sharon A. O'Toole, Eugen Ancuta, Ream Langhe, Dolores J. Cahill, Mairead Murphy, Cara Martin, Lynda McEvoy, Cathy Spillane, Orla Sheils, Emmanuel Petricoin, Lance Liotta, John J. O'Leary -- 25. Early Markers for Neoplastic Lesions of the Uterine Cervix / Pablo Conesa-Zamora -- 26. Biomarkers in Diagnosis of Papillary Thyroid Carcinoma / Marisa CaNadas-Garre, Nuria MuNoz PErez, JesUs MarIa Viliar del Moral, JosE Antonio FerrOn Orihuela, JosE Manuel Llamas-Elvira -- 27. Blomolecular Markers for Improving Management of Follicular and Medullary Thyroid Cancer / Umut Mousa, Cuneyd Anil, Serife Mehlika Isudak, Alptekin Gursoy, Angela Carpi -- Part VII. Hematological Cancers -- 28. Biomarkers in Myelodysplastic Syndrome / NEstor L. LOpez Corrales, Vasco Ariston de Carvalho Azevedo -- 29. Markers for Diagnosis, Prognosis, and Therapy of Acute Myeloid Leukemia / Ota Fuchs -- 30. Biomarkers in Hodgkin's Lymphoma / Esin Demir, Burak Yilmaz, Mehmet Gunduz, Esra Gunduz -- 31. Multiple Myeloma and Evolution of Novel Biomarkers and Therapies / Michael Byrne, Joseph Katz, Jan S. Moreb -- Part VIII. Melanoma -- 32. Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma / Eijun Itakura, Alistair J. Cochran -- Index. Publisher Marketing: Gleaning information from more than 100 experts in the field of cancer diagnosis, prognosis, and therapy worldwide, Cancer Biomarkers: Non-Invasive Early Diagnosis and Prognosis determines the significance of clinical validation approaches for several markers. This book examines the use of noninvasive or minimally invasive molecular cancer markers that are under development or currently in use. It deals with a majority of commonly prevalent cancers and can help anyone working in the health-care industry to recommend or develop early diagnostics, at-risk tests, and prognostic biomarkers for various cancers. It explores the practice of determining biomarkers by their characteristics and relative methodologies, and presents the most recent data as well as a number of current and upcoming early diagnostic noninvasive molecular markers for many common cancers. It also considers the sensitivity and specificity of markers, biomarker market, test providers, and patent information. Approximately 30-35 Cancer Specific Noninvasive Molecular Diagnostic Markers in a Single Volume The book details the general and technical aspects of noninvasive cancer markers. It covers imaging, cutting-edge molecular technologies for biomarker development, and noninvasive or minimally invasive sources of molecular markers, as well as quality control and ethical issues in cancer biomarker discovery. It also provides a detailed account of brain, head and neck, and oral cancer markers, and provides information on a number of gastrointestinal cancers, lung cancer, and mesothelioma markers. Emphasizes the Importance of Volatile Markers in Early Cancer Diagnosis Presents noninvasive early molecular markers in urological cancers Describes gynecological and endocrine cancer markers Details noninvasive markers of breast, ovarian, cervical, and thyroid cancers Addresses hematological malignancies Contains information on noninvasive molecular markers in myelodys

Contributor Bio:  Verma, Mukesh Mukesh Verma, Barbara K. Dunn, and Asad Umar are with the National Cancer Institute, NIH, in Rockville, Maryland.